Epcoritamab in Combination With R-CHOP for Patients With Aggressive Non-Hodgkin Lymphoma

PRIMARY OBJECTIVES: I. To evaluate the incidence and severity of all grade CRS cytokine release syndrome (CRS) in arm A and arm B. SECONDARY OBJECTIVES: I. To determine the safety and tolerability of the combination of epcoritamab and rituximab, cyclophosphamide, hydroxydaunorubicin, oncovin, prednisolone (R-CHOP) in both arms and individually. II. The anti-tumor activity of epcoritamab + R-CHOP. III. To evaluate duration of response (DOR), progression-free survival (PFS), and overall survival (OS). EXPLORATORY OBJECTIVES: I. To evaluate changes in serum cytokine levels with epcoritamab treatment and explore their association with the incidence and severity of CRS. II. To characterize peripheral T-cell subsets and activation states and explore phenotypic profiles associated with CRS. OUTLINE: Participants will receive epcoritamab combined with R-CHOP chemotherapy and dexamethasone. The treatment will be delivered in up to 8 cycles in an outpatient setting. participants are followed at Week 8 and every 3 months for up to one year, or until improvement or stabilization, or until new therapy begins, whichever occurs first.